End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
8.9 MYR | +5.45% | +5.58% | -4.20% |
May. 29 | Nicotine-like chemicals in U.S. vapes may be more potent than nicotine, FDA says | RE |
May. 29 | Nicotine-like chemicals in U.S. vapes may be more potent than nicotine, FDA says | RE |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Strengths
- The company has a low valuation given the cash flows generated by its activity.
- This company will be of major interest to investors in search of a high dividend stock.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
- The company appears highly valued given the size of its balance sheet.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- Revenue estimates are regularly revised downwards for the current and coming years.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- Most analysts agree on a negative opinion with regard to the stock. Indeed, the average consensus issues recommendations to underperform or sell.
- The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
- Over the past twelve months, analysts' opinions have been revised negatively.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Tobacco
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-4.20% | 540M | A- | ||
+14.65% | 79.44B | B- | ||
-7.71% | 63.79B | B | ||
+22.14% | 50.27B | A- | ||
-3.91% | 6.81B | A- | ||
-17.88% | 5.26B | A- | ||
-5.50% | 2.4B | C- | ||
-8.00% | 2.21B | C- | ||
-36.61% | 1.51B | - | ||
-2.82% | 1.3B | D+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- BAT Stock
- Ratings British American Tobacco (Malaysia)